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ABSTRACT 
Background:The trial aim was to determine if for women with needle biopsy proven 
positive node on preoperative axillary ultrasound(AUS), the number of abnormal 
nodes seen on AUS is a predictor of number of positive nodes at histology.  
Methods:This prospective multicentre cohort study included consecutive patients 
with early breast cancer who had needle biopsy proven positive node on AUS and 
underwent ALND between October 2015 and July 2016. The number of abnormal 
nodes at preoperative AUS was recorded by breast radiologists or radiographers. 
Results:123 patients were included in the study. Median age of the women was 
62(range 30 to 93) years. 54 of 123(44%) women had one abnormal node while 
69(56%) had multiple abnormal nodes on AUS. 40 of 123(33%) women had two or 
less nodes with metastases at histology after ALND. Tumours 20 mm or less(P < 
0.001) and one abnormal node on AUS(P < 0.001) were associated with two or less 
nodes with metastases at ALND. Both remained significant in logistic regression 
analysis. The likelihood of at least three metastases based on the combination of these 
two factors had 95% sensitivity(79 of 83), 35% specificity(14 of 40), negative 
predictive value of 78%(14 of 18) and positive predictive value of 75%(79 of 105).  
Conclusion:Among women with needle biopsy proven positive nodes, around 3 in 4 
women(78%) with invasive tumour size 2 cm or less and one abnormal node on AUS 
have 2 or less positive nodes at ALND. These women are overtreated by upfront 
ALND and can be offered SNB.  
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Introduction 
Preoperative axillary ultrasound (AUS) is performed routinely in many centres to 
stage the axilla and abnormal nodes are subjected to fine needle aspiration cytology 
(FNA) or core biopsy{ ADDIN REFMGR.CITE 
<Refman><Cite><Year>2009</Year><RecNum>260</RecNum><IDText>Breast 
cancer (early &amp; locally advanced): diagnosis and treatment</IDText><MDL 
Ref_Type="Journal"><Ref_Type>Journal</Ref_Type><Ref_ID>260</Ref_ID><Titl
e_Primary>Breast cancer (early &amp; locally advanced): diagnosis and 
treatment</Title_Primary><Date_Primary>2009</Date_Primary><Keywords>Breast
</Keywords><Keywords>diagnosis</Keywords><Reprint>Not in 
File</Reprint><Periodical>http://guidance.nice.org.uk/CG80</Periodical><ZZ_Journ
alStdAbbrev><f 
name="System">http://guidance.nice.org.uk/CG80</f></ZZ_JournalStdAbbrev><ZZ
_WorkformID>1</ZZ_WorkformID></MDL></Cite></Refman>}. Generally, 
women with needle biopsy proven positive nodes proceed to axillary lymph node 
dissection (ALND) as ultrasound detected nodal disease (FNA or core biopsy 
positive) has higher tumour burden compared with sentinel node biopsy (SNB) 
detected nodal metastases{ ADDIN REFMGR.CITE { ADDIN EN.CITE.DATA }}. 
However, around 40 per cent of women with ultrasound detected nodal disease (FNA 
or core biopsy positive) are found to have two or less nodes with macrometastases at 
ALND{ ADDIN REFMGR.CITE { ADDIN EN.CITE.DATA }}. ALND is often 
associated with debilitating side effects such as arm swelling, numbness, shoulder 
function impairment and reduced quality of life compared with sentinel node biopsy 
(SNB){ ADDIN REFMGR.CITE { ADDIN EN.CITE.DATA }}.These women are 
overtreated by ALND as the 1 or 2 nodes with macrometastases are likely to be 
removed at the time of sentinel node biopsy and the role of further axillary treatment 
in this subgroup has been challenged by ACOSOG Z0011{ ADDIN REFMGR.CITE { 
ADDIN EN.CITE.DATA }} and is being questioned by POSNOC{ ADDIN 
REFMGR.CITE 
<Refman><Cite><Author>Goyal</Author><Year>2015</Year><RecNum>428</Re
cNum><IDText>POSNOC: A Randomised Trial Looking at Axillary Treatment in 
Women with One or Two Sentinel Nodes with Macrometastases</IDText><MDL 
Ref_Type="Journal"><Ref_Type>Journal</Ref_Type><Ref_ID>428</Ref_ID><Titl
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e_Primary>POSNOC: A Randomised Trial Looking at Axillary Treatment in Women 
with One or Two Sentinel Nodes with 
Macrometastases</Title_Primary><Authors_Primary>Goyal,A.</Authors_Primary><
Authors_Primary>Dodwell,D.</Authors_Primary><Date_Primary>2015/12</Date_P
rimary><Keywords>WOMEN</Keywords><Reprint>Not in 
File</Reprint><Start_Page>692</Start_Page><End_Page>695</End_Page><Periodi
cal>Clin.Oncol.(R.Coll.Radiol.)</Periodical><Volume>27</Volume><Issue>12</Iss
ue><Misc_3>S0936-6555(15)00312-X [pii];10.1016/j.clon.2015.07.005 
[doi]</Misc_3><Address>Royal Derby Hospital, Derby, UK. Electronic address: 
amit.goyal@nhs.net&#xA;St James Hospital, Leeds, 
UK</Address><Web_URL>PM:26254841</Web_URL><ZZ_JournalFull><f 
name="System">Clin.Oncol.(R.Coll.Radiol.)</f></ZZ_JournalFull><ZZ_WorkformI
D>1</ZZ_WorkformID></MDL></Cite></Refman>}. The challenge is to reliably 
identify this subgroup that can proceed to sentinel node biopsy rather than ALND.  
 
In patients with AUS detected nodal metastasis (FNA or core biopsy positive), we 
previously showed that tumour size is a strong predictor and tumour histology a weak 
predictor of number of nodes with macrometastases at ALND{ ADDIN 
REFMGR.CITE { ADDIN EN.CITE.DATA }}. Together, the predictive ability is low 
and needs to be improved to reliably select patients who can proceed to SNB instead 
of ALND. Two retrospective studies have shown that for FNA or core biopsy proven 
node positive patients, the number of abnormal nodes on preoperative AUS is 
associated with the extent of nodal disease at histology after ALND{ ADDIN 
REFMGR.CITE { ADDIN EN.CITE.DATA }}.The aim of the present prospective 
study was to determine if the number of abnormal nodes seen on preoperative AUS in 
combination with tumour characteristics reliably predicts the number of positive 
nodes at histology after ALND and whether this information can be used in clinical 
practice to identify patients with two or less positive nodes who may be offered SNB 
rather than ALND.  
 
Methods 
A mix of screening and symptomatic women with FNA or core biopsy proven 
positive node on axillary ultrasound (AUS positive) who subsequently underwent 
ALND between October 2015 and July 2016were included in this prospective audit 
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from six centres (Derby, Leeds, Leicester, Kettering, Cambridge and Dundee). 
Axillary ultrasound was performed by breast radiologists or radiographers. A node 
was considered abnormal if there was cortical thickening, loss or displacement of 
fatty hilum or round shape. The number of abnormal nodes at pre-operative 
ultrasound examination was recorded. Patient demographics, tumour size, tumour 
grade, tumour histology, receptor status, number of nodes removed, number of 
positive nodes and presence or absence of extranodal invasion were recorded. Women 
who received neoadjuvant chemotherapy or did not undergo surgery were excluded. 
The study was registered and approved as a multicentre audit locally. 
 
Statistical analysis 
Tumour size had a substantially skewed distribution and was analysed using the 
Mann–Whitney U test. The 2 test was used for evaluation of tumour pathology and 
all binary variables. Tumour grade and number of abnormal nodes on ultrasound scan 
are an ordinal scale, for which the Mann–Whitney U test was used. Multiple logistic 
regression analysis was performed to identify significant predictors, for which 
sensitivity, specificity, and negative and positive predictive values were calculated. P 
< 0.050 was considered statistically significant.  
 
Results 
A total of 123 women who had a needle biopsy proven positive node on preoperative 
AUS were eligible for inclusion in the study. All women underwent breast surgery 
(breast-conserving surgery or mastectomy) and ALND. The median age of the women 
was 62 (range 30 to 93) years. Patient demographics, number of abnormal nodes on 
preoperative AUS, tumour characteristics and findings at ALND are shown in Table 
1.54 of 123 (44%) women had one abnormal node while 69 (56%) had two or more 
abnormal nodes on preoperative AUS. 40 of 123 (33%) women had two or less nodes 
with metastases at histology after ALND. Nodes with extranodal invasion were 
present in 75 of 123 patients (61 per cent). 
 
Predictors of number of nodes with metastases at ALND 
Tumours 20 mm or less (P < 0.001) and one abnormal node on preoperative AUS (P < 
0.001) were associated with two or less nodes with metastases at ALND (Table 2). 30 
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of 54 women (55.6 per cent) with one abnormal node on preoperative AUS, and 17 of 
29 women with T1 tumour (58.6 per cent) had two or less nodes with metastases at 
ALND (Table 2).  
 
In a logistic regression analysis with two categorical factors (Table 3), tumour size 
(grouped) (2 test p=0.018) and number of abnormal nodes on preoperative AUS (2 
test p=0.001), both contribute significantly to the predictive model but the evidence is 
stronger for the number of abnormal nodes on preoperative AUS. Table 4 summarizes 
the degree of prediction of the likelihood of at least three metastases based on these 
two factors. This combination had 95 per cent sensitivity (79 of 83), 35 per cent 
specificity (14 of 40), a negative predictive value of 78 per cent (14 of 18) and 
positive predictive value of 75 per cent (79 of 105) for heavy nodal burden (≥3 
positive nodes). 
 
Discussion 
Our study shows that among women with needle biopsy proven positive nodes, the 
combination of number of abnormal nodes on AUS and tumour size can reliably 
identify patients who may be offered SNB thus less risk of arm morbidity compared 
with ALND{ ADDIN REFMGR.CITE { ADDIN EN.CITE.DATA }}. Our study 
shows that less than 1 in 4 women (22 per cent) with invasive tumour size 2 cm or 
less and one abnormal node on preoperative AUS are found to have more than two 
positive nodes at histology after ALND, and thus are likely to need a second operation 
(completion ALND) after initial SNB. The majority of these women (78 per cent) in 
our study were found to have two or less positive nodes at histology after ALND. The 
role of further axillary treatment in women with two or less positive nodes at SNB 
was challenged by ACOSOG Z0011{ ADDIN REFMGR.CITE { ADDIN 
EN.CITE.DATA }}. American Society of Clinical Oncology guidelines were updated 
to recommend omission of ALND in women with one to two metastatic sentinel 
nodes who undergo breast-conserving surgery with whole-breast radiotherapy{ 
ADDIN REFMGR.CITE 
<Refman><Cite><Author>Lyman</Author><Year>2016</Year><RecNum>468</R
ecNum><IDText>Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast 
Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 
  
{ PAGE   \* MERGEFORMAT } 
 
</IDText><MDL 
Ref_Type="Journal"><Ref_Type>Journal</Ref_Type><Ref_ID>468</Ref_ID><Titl
e_Primary><f name="Times New Roman">Sentinel Lymph Node Biopsy for Patients 
With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical 
Practice Guideline Update 
</f></Title_Primary><Authors_Primary>Lyman,G.H.</Authors_Primary><Authors_
Primary>Somerfield,M.R.</Authors_Primary><Authors_Primary>Bosserman,L.D.</
Authors_Primary><Authors_Primary>Perkins,C.L.</Authors_Primary><Authors_Pri
mary>Weaver,D.L.</Authors_Primary><Authors_Primary>Giuliano,A.E.</Authors_
Primary><Date_Primary>2016/12/12</Date_Primary><Keywords>Sentinel lymph 
node</Keywords><Keywords>Sentinel Lymph Node 
Biopsy</Keywords><Keywords>Biopsy</Keywords><Keywords>Breast</Keyword
s><Keywords>Breast cancer</Keywords><Reprint>Not in 
File</Reprint><Start_Page>561</Start_Page><End_Page>564</End_Page><Periodi
cal>J Clin 
Oncol</Periodical><Volume>35</Volume><Issue>5</Issue><ZZ_JournalFull><f 
name="System">J Clin 
Oncol</f></ZZ_JournalFull><ZZ_WorkformID>1</ZZ_WorkformID></MDL></Cit
e></Refman>}. However, a recent survey shows that radiation oncologists in the US 
treat the undissected axilla with radiotherapy rather than omitting axillary treatment{ 
ADDIN REFMGR.CITE 
<Refman><Cite><Author>Azghadi</Author><Year>2016</Year><RecNum>436</
RecNum><IDText>Practice Patterns of Radiation Field Design for Sentinel Lymph 
Node-Positive Early-Stage Breast Cancer</IDText><MDL 
Ref_Type="Journal"><Ref_Type>Journal</Ref_Type><Ref_ID>436</Ref_ID><Titl
e_Primary>Practice Patterns of Radiation Field Design for Sentinel Lymph Node-
Positive Early-Stage Breast 
Cancer</Title_Primary><Authors_Primary>Azghadi,S.</Authors_Primary><Authors
_Primary>Daly,M.</Authors_Primary><Authors_Primary>Mayadev,J.</Authors_Pri
mary><Date_Primary>2016/10</Date_Primary><Keywords>Axilla</Keywords><K
eywords>Breast</Keywords><Keywords>Breast 
cancer</Keywords><Keywords>California</Keywords><Keywords>Medicine</Key
words><Keywords>methods</Keywords><Keywords>radiotherapy</Keywords><K
eywords>Risk</Keywords><Keywords>Risk 
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Factors</Keywords><Keywords>Sentinel lymph 
node</Keywords><Keywords>therapy</Keywords><Keywords>United 
States</Keywords><Reprint>Not in 
File</Reprint><Start_Page>410</Start_Page><End_Page>417</End_Page><Periodi
cal>Clin.Breast 
Cancer</Periodical><Volume>16</Volume><Issue>5</Issue><Misc_3>S1526-
8209(16)30105-7 [pii];10.1016/j.clbc.2016.05.009 
[doi]</Misc_3><Address>Department of Radiation Oncology, University of 
California, Davis, School of Medicine, Sacramento, CA&#xA;Department of 
Radiation Oncology, University of California, Davis, School of Medicine, 
Sacramento, CA&#xA;Department of Radiation Oncology, University of California, 
Davis, School of Medicine, Sacramento, CA. Electronic address: 
jyoti.mayadev@ucdmc.ucdavis.edu</Address><Web_URL>PM:27266803</Web_U
RL><ZZ_JournalFull><f name="System">Clin.Breast 
Cancer</f></ZZ_JournalFull><ZZ_WorkformID>1</ZZ_WorkformID></MDL></C
ite></Refman>}. The ACOSOG Z0011 study had various limitations, as a result 
clinical practice has not changed in most centres in the UK, Australia and New 
Zealand. Women with 1 or 2 nodes with macrometastases at SNB in these centres are 
either offered participation in the POSNOC study{ ADDIN REFMGR.CITE 
<Refman><Cite><Author>Goyal</Author><Year>2015</Year><RecNum>428</Re
cNum><IDText>POSNOC: A Randomised Trial Looking at Axillary Treatment in 
Women with One or Two Sentinel Nodes with Macrometastases</IDText><MDL 
Ref_Type="Journal"><Ref_Type>Journal</Ref_Type><Ref_ID>428</Ref_ID><Titl
e_Primary>POSNOC: A Randomised Trial Looking at Axillary Treatment in Women 
with One or Two Sentinel Nodes with 
Macrometastases</Title_Primary><Authors_Primary>Goyal,A.</Authors_Primary><
Authors_Primary>Dodwell,D.</Authors_Primary><Date_Primary>2015/12</Date_P
rimary><Keywords>WOMEN</Keywords><Reprint>Not in 
File</Reprint><Start_Page>692</Start_Page><End_Page>695</End_Page><Periodi
cal>Clin.Oncol.(R.Coll.Radiol.)</Periodical><Volume>27</Volume><Issue>12</Iss
ue><Misc_3>S0936-6555(15)00312-X [pii];10.1016/j.clon.2015.07.005 
[doi]</Misc_3><Address>Royal Derby Hospital, Derby, UK. Electronic address: 
amit.goyal@nhs.net&#xA;St James Hospital, Leeds, 
UK</Address><Web_URL>PM:26254841</Web_URL><ZZ_JournalFull><f 
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name="System">Clin.Oncol.(R.Coll.Radiol.)</f></ZZ_JournalFull><ZZ_WorkformI
D>1</ZZ_WorkformID></MDL></Cite></Refman>} that is evaluating the role of 
further axillary treatment in these patients or outside the study may be offered axillary 
radiotherapy that has less functional sequelae than ALND{ ADDIN REFMGR.CITE { 
ADDIN EN.CITE.DATA }}. 
This multicentre prospective study validates our previous findings from a 
retrospective single centre study{ ADDIN REFMGR.CITE { ADDIN 
EN.CITE.DATA }}. Tumour size remained a significant predictor, while tumour 
histology lost its weak predictive ability for more than two positive nodes at ALND in 
the present study. The number of abnormal nodes on preoperative AUS emerged as 
the strongest predictor.  
 
Similar to our study, Hieken et al.{ ADDIN REFMGR.CITE 
<Refman><Cite><Author>Hieken</Author><Year>2013</Year><RecNum>449</R
ecNum><IDText>Preoperative axillary imaging with percutaneous lymph node 
biopsy is valuable in the contemporary management of patients with breast 
cancer</IDText><MDL 
Ref_Type="Journal"><Ref_Type>Journal</Ref_Type><Ref_ID>449</Ref_ID><Titl
e_Primary>Preoperative axillary imaging with percutaneous lymph node biopsy is 
valuable in the contemporary management of patients with breast 
cancer</Title_Primary><Authors_Primary>Hieken,T.J.</Authors_Primary><Authors
_Primary>Trull,B.C.</Authors_Primary><Authors_Primary>Boughey,J.C.</Authors
_Primary><Authors_Primary>Jones,K.N.</Authors_Primary><Authors_Primary>Re
ynolds,C.A.</Authors_Primary><Authors_Primary>Shah,S.S.</Authors_Primary><
Authors_Primary>Glazebrook,K.N.</Authors_Primary><Date_Primary>2013/10</D
ate_Primary><Keywords>Adult</Keywords><Keywords>Aged</Keywords><Keyw
ords>Aged,80 and 
over</Keywords><Keywords>Axilla</Keywords><Keywords>Axillary 
dissection</Keywords><Keywords>Biopsy</Keywords><Keywords>Biopsy,Needle
</Keywords><Keywords>Breast</Keywords><Keywords>Breast 
cancer</Keywords><Keywords>Breast 
Neoplasms</Keywords><Keywords>Female</Keywords><Keywords>Humans</Ke
ywords><Keywords>Lymph Nodes</Keywords><Keywords>Lymphatic 
Metastasis</Keywords><Keywords>Magnetic Resonance 
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Imaging</Keywords><Keywords>methods</Keywords><Keywords>Middle 
Aged</Keywords><Keywords>pathology</Keywords><Keywords>surgery</Keywo
rds><Keywords>ultrasonography</Keywords><Keywords>Ultrasonography,Interven
tional</Keywords><Reprint>Not in 
File</Reprint><Start_Page>831</Start_Page><End_Page>838</End_Page><Periodi
cal>Surgery</Periodical><Volume>154</Volume><Issue>4</Issue><Misc_3>S003
9-6060(13)00419-4 [pii];10.1016/j.surg.2013.07.017 
[doi]</Misc_3><Address>Department of Surgery, Mayo Clinic, Rochester, MN. 
Electronic address: 
hieken.tina@mayo.edu</Address><Web_URL>PM:24074422</Web_URL><ZZ_Jo
urnalFull><f 
name="System">Surgery</f></ZZ_JournalFull><ZZ_WorkformID>1</ZZ_Workfor
mID></MDL></Cite></Refman>} found that the number of abnormal nodes on 
ultrasound scan (one vs. multiple) predicted the extent of nodal tumour burden at 
ALND. Among needle biopsy positive women, 2 in 3 women with one abnormal node 
on AUS had two or less positive nodes at ALND. Likewise Farrell et al.{ ADDIN 
REFMGR.CITE { ADDIN EN.CITE.DATA }} reported increasing tumour burden 
with the multiple abnormal nodes on preoperative AUS. The median number of nodes 
with cancer on ALND was 3 (range 1-21), 5 (range 1-28) and 7 (range 1-41) for 
patients with one, two and more than two abnormal nodes on preoperative AUS.  
 
It may be argued that needle biopsy is not needed in women with invasive tumour 2 
cm or less and one abnormal node on preoperative AUS and they can proceed to SNB. 
The concern is that the biopsied node with metastases may be left in the axilla at 
SNB. Nathanson et al.{ ADDIN REFMGR.CITE 
<Refman><Cite><Author>Nathanson</Author><Year>2007</Year><RecNum>451
</RecNum><IDText>Preoperative identification of the sentinel lymph node in breast 
cancer</IDText><MDL 
Ref_Type="Journal"><Ref_Type>Journal</Ref_Type><Ref_ID>451</Ref_ID><Titl
e_Primary>Preoperative identification of the sentinel lymph node in breast 
cancer</Title_Primary><Authors_Primary>Nathanson,S.D.</Authors_Primary><Aut
hors_Primary>Burke,M.</Authors_Primary><Authors_Primary>Slater,R.</Authors_
Primary><Authors_Primary>Kapke,A.</Authors_Primary><Date_Primary>2007/11
</Date_Primary><Keywords>Axilla</Keywords><Keywords>Biopsy</Keywords><
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Keywords>Breast</Keywords><Keywords>Breast 
cancer</Keywords><Keywords>Breast 
Neoplasms</Keywords><Keywords>Carcinoma,Ductal,Breast</Keywords><Keywor
ds>Carcinoma,Intraductal,Noninfiltrating</Keywords><Keywords>Carcinoma,Lobul
ar</Keywords><Keywords>diagnosis</Keywords><Keywords>diagnostic 
imaging</Keywords><Keywords>Disease 
Progression</Keywords><Keywords>Female</Keywords><Keywords>Humans</Ke
ywords><Keywords>Lymphatic 
Metastasis</Keywords><Keywords>methods</Keywords><Keywords>Middle 
Aged</Keywords><Keywords>pathology</Keywords><Keywords>Preoperative 
Care</Keywords><Keywords>Prognosis</Keywords><Keywords>Risk 
Factors</Keywords><Keywords>Sentinel lymph 
node</Keywords><Keywords>Sentinel Lymph Node 
Biopsy</Keywords><Keywords>surgery</Keywords><Keywords>ultrasonography<
/Keywords><Reprint>Not in 
File</Reprint><Start_Page>3102</Start_Page><End_Page>3110</End_Page><Perio
dical>Ann.Surg 
Oncol.</Periodical><Volume>14</Volume><Issue>11</Issue><Misc_3>10.1245/s1
0434-007-9494-5 [doi]</Misc_3><Address>Department of Surgery, Henry Ford 
Health System, 2799 West Grand Boulevard, Detroit, Michigan 48202, USA. 
dnathan1@hfhs.org</Address><Web_URL>PM:17661149</Web_URL><ZZ_Journa
lFull><f name="System">Ann.Surg 
Oncol.</f></ZZ_JournalFull><ZZ_WorkformID>1</ZZ_WorkformID></MDL></Ci
te></Refman>} reported a 78 per cent concordance between the biopsied node and 
sentinel node. Therefore, a clip can be placed in the needle biopsy positive node and a 
x-ray of the specimen should be performed at SNB to ensure that the clipped node is 
removed. The problem is to successfully localise the clipped node intra-operatively. 
Z1071 shows that in patients with 3 sentinel nodes identified, the clipped node is the 
sentinel node in 78 per cent cases{ ADDIN REFMGR.CITE { ADDIN 
EN.CITE.DATA }}. Alternative strategies are to mark the clipped node using a wire, 
sterile black carbon suspension (SpotTM){ ADDIN REFMGR.CITE { ADDIN 
EN.CITE.DATA }}or radioactive iodine seed(I125){ ADDIN REFMGR.CITE { 
ADDIN EN.CITE.DATA }}. If the clipped node is not retrieved, patients should 
undergo ALND.  
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The simple and less expensive technique of tattooing the positive node at the time of 
needle biopsy is attractive but remains to be standardised and tested in further studies. 
The dye may be used both to mark the malignant node and visualise the node intra-
operatively{ ADDIN REFMGR.CITE { ADDIN EN.CITE.DATA }}. 
Our study is notable as this is a prospective study and the first UK data to allow 
selection of patients who can be offered SNB. There is a potential to improve the 
predictive tool as around half of the women with 2 or less positive nodes at ALND do 
not meet the criteria (tumour size 2 cm or less and one abnormal node on AUS) and 
will be offered upfront ALND. This study may be criticised as there may be inter-
operator and inter-site variability in defining an ‘abnormal node’ at preoperative AUS. 
However, our study reflects what is happening in the real world and this allows the 
results to be generalised to other centres. Additionally, the variability is unlikely to 
affect the results as the entry point is women with a needle biopsy proven positive 
node rather than an ‘abnormal node’.  
 
To conclude, among women with needle biopsy proven positive nodes, the present 
study shows that around 3 in 4 patients with invasive tumour size 2 cm or less and one 
abnormal node on preoperative AUS have 2 or less positive nodes at ALND. These 
women are overtreated by upfront ALND and can be offered SNB.  
 
 
COLLABORATORS (in alphabetical order) 
Mark Bagnall (Department of Radiology, Royal Derby Hospital, Derby), Pieta Ipatti 
(Diagnostic Radiology, Oulu University Hospital, Finland), Anne Turnbull 
(Department of Radiology, Royal Derby Hospital, Derby), Joanne York (Department 
of Radiology, Royal Derby Hospital, Derby). 
 
 
 
 
 
 
 
  
{ PAGE   \* MERGEFORMAT } 
 
 
 
 
 
 
 
 
{ ADDIN REFMGR.REFLIST } 
 
 
 
 
 
 
 
 
Table 1 Characteristics of patients 
 
Characteristic n = 123 
Age y (median[range]) 62[30-93] 
Presentation of breast cancer  
symptomatic 98 (80%) 
screen detected  25 (20%) 
Number of abnormal nodes on ultrasound scan 
1 54 (44%) 
2 28 (23%) 
>2 41 (33%) 
Type of surgery  
Wide local excision 46 (37%) 
Mastectomy 77 (63%) 
Total no. of nodes removed, mean [SD] 19.9 [8.0] 
Total number of positive lymph nodes, 
mean [SD] 
6.6 [7.2] 
Number of positive lymph nodes  
1 27 (22%) 
2 13 (11%) 
3 16 (13%) 
≥4 67 (54%) 
Extranodal invasion  
present 75 (61%) 
absent 44 (36%) 
not reported or uncertain 4 (3%) 
Tumour size  
Up to 20 mm 29 (24%) 
20.1–50 mm 72 (59%) 
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Over 50 mm 22 (18%) 
Multifocality  
Present 97 (81%) 
Absent 23 (19%) 
Tumour grade  
I 8 (7%) 
II 41 (33%) 
III 74 (60%) 
Tumour pathology  
Invasive ductal 93 (76%) 
Invasive lobular 15 (12%) 
Other 15 (12%) 
Lymphovascular invasion  
present 75 (64%) 
absent 43 (36%) 
ER status  
positive 93 (76%) 
negative 30 (24%) 
HER2 status  
positive 96 (79%) 
negative 25 (21%) 
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Table 2 Tumour characteristics and the number of nodes with metastases identified at 
axillary lymph node dissection (n=123) 
 
Variable 1 to 2 
(n = 40) 
3 or more 
(n = 83) 
p-value 
Type of surgery    
Wide local excision 18 (45%) 28 (34%) 0.23‡ 
Mastectomy 22 (55%) 55 (66%)  
Number of abnormal nodes on 
ultrasound scan 
   
1 30 (75%) 24 (29%) <0.001¶ 
2 7 (18%) 21 (25%)  
>2 3 (8%) 38 (46%)  
Tumour size    
Up to 20 mm 17 (43%) 12 (14%) <0.001¶ 
20.1–50 mm 22 (55%) 50 (60%)  
Over 50 mm 1 (3%) 21 (25%)  
Multifocality    
Present 30 (79%) 67 (82%) 0.72‡ 
Absent 8 (21%) 15 (18%)  
Tumour grade    
I 2 (5%) 6 (7%) 0.57¶ 
II 16 (40%) 25 (30%)  
III 22 (55%) 52 (63%)  
Tumour pathology    
Invasive ductal 35 (88%) 58 (70%) 0.052‡ 
Invasive lobular 1 (3%) 14 (17%)  
Other 4 (10%) 11 (13%)  
Lymphovascular invasion    
present 21 (54%) 54 (68%) 0.12‡ 
absent 18 (46%) 25 (32%)  
ER status    
positive 8 (20%) 22 (27%) 0.43‡ 
negative 32 (80%) 61 (73%)  
HER2 status    
positive 11 (28%) 14 (17%) 0.16‡ 
negative 28 (72%) 68 (83%)  
‡2 test and ¶Mann–Whitney U test. 
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Table 3 Logistic regression for two factors, tumour size and number of abnormal 
lymph nodes on preoperative AUS 
 
 N Odds ratio 95% confidence limits 
Tumour size (mm)    
≥ 50 22 1.0  
21-50 72 0.26 0.055, 1.20 
 20 29 0.085 0.022, 0.34 
No. of abnormal nodes on AUS    
More than 2  41 1.0  
2 28 0.29 0.032, 2.54 
1 54 0.084 0.009, 0.80 
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Table 4 Predictive value of tumour size and number of abnormal lymph nodes on 
preoperative AUS 
 
 
 No. of nodes with metastases 
Total ≤ 2  ≥3  
Tumour size ≤ 20 mm and 1 
abnormal node on AUS 
14 4 18 
Tumour size > 20 mm or ≥2 
abnormal nodes on AUS 
26 79 105 
    
Total 40 83 123 
 
Summary statistics for heavy nodal burden (≥3 positive nodes) as a predictor of 
presence of 3 or more metastases, with 95% confidence limits: 
 
Sensitivity 95% (88%, 98%) 
Specificity 35% (22%, 50%) 
Negative predictive value 78% (55%, 91%) 
Positive predictive value 75% (66%, 83%). 
 
 
 
 
